AUA 2016 Annual Meeting Coverage

Identification of Candidates for Radical Prostatectomy with TPMB

San Diego—The identification of men with prostate cancer who are best suited for radical prostatectomy may be aided by use of intra-prostatic staging by transperineal mapping biopsy (TPMB). E. David Crawford, MD, and colleagues recently conducted an analysis of transrectal ultrasonography (TRUS) biopsy positive men with minimal disease, biopsy negative, and biopsy naïve men who had TPMB followed by radical ... Read More »

IMAAGEN Trial Secondary End Points Updated

San Diego—Researchers led by Charles Ryan, MD, presented updated results of secondary end points of the IMAAGEN (Impact of Abiraterone Acetate in Prostate Specific Antigen) study at the AUA 2016 Annual meeting during a session titled Impact of Abiraterone Acetate in Prostate Specific Antigen Trial Update: Effect of Abiraterone Acetate and Low Dose Prednisone on Prostate-Specific Antigen and Radiographic Disease ... Read More »

CTC Cells Predictors of Survival in Men Treated with Abiraterone Acetate

San Diego—Among patients with metastatic castration resistant prostate cancer (mCRPC), circulating tumor cells (CTCs) are established biomarkers to predict response to chemotherapy. A recent biomarker panel comprising CTC has also demonstrated predictive value for survival in men treated with abiraterone acetate following chemotherapy in the COU-AA-301 pivotal trial. Researchers led by Christian Meyer, MD, presented long-term data of a sub-analysis ... Read More »

Abiraterone Acetate Provides Survival Benefit in Post-Chemotherapy Setting

San Diego—In a retrospective cohort study conducted by Alice Dragomir, MSc, PhD, and colleagues, there was survival benefit among patients with metastatic castration resistant prostate cancer (mCRPC) receiving abiraterone acetate in combination with chemotherapy compared with patients receiving chemotherapy only. The researchers reported results of the study at the AUA 2016 Annual Meeting in a presentation titled Use of Abiraterone ... Read More »

Researchers Develop Gene Classifier to Aid Treatment Decisions

San Diego—With the increasing use of precision medicine, there has not yet been a broad impact of genomic classifications of prostate cancer on patient care, according to researchers led by Sungyong You, PhD. The research team presented results of an integrative analysis of 14 disease-related pathways in more than 4600 clinical specimens and 25 prostate cancer preclinical models during a ... Read More »

Disadvantages of PSA Screening Mentioned Less in Decision-Making Process

San Diego—Screening for prostate cancer based on prostate specific antigen level is a controversial issue in the United States. Several guidelines and healthcare organizations, including the American Urological Association, recommend counseling and shared-decision making for patients considering PSA screening. Researchers, led by Nawar Hanna, MD, recently conducted an analysis to identify patient characteristics associated with physician counseling. They reported results ... Read More »

PSA Screening Rates Drop after 2011 USPSTF Recommendations

San Diego—Given concerns about over-diagnosis and over-treatment of prostate cancer in the United States, there is ongoing debate regarding prostate specific antigen (PSA) screening. In 2011, the United States Preventive Services Task Force (USPSTF) released a draft of recommendations advising against PSA screening in all men (the draft was finalized in May 2012). Firas Abdollah, MD, and colleagues recently conducted ... Read More »

Quality of Life Improved with Concurrent Administration of Radium-223 and Abiraterone Acetate

San Diego—Results of a phase 2 study (NCT02097303) designed to assess the safety and quality of life of concurrent use of radium Ra 223 dichloride (RA-223) and abiraterone acetate (AA) were reported during a poster session at the AUA 2016 Annual Meeting by Neal Shore, MD, and colleagues. The study included the largest cohort of subjects to date. The poster ... Read More »

Restriction of Carbohydrates Improves Insulin Sensitivity in Men on ADT

San Diego—Diabetes, weight gain, increased fat mass, and osteoporosis are examples of metabolic side effects of androgen deprivation therapy (ADT). Researchers, led by Stephen Freedland, MD, conducted a phase 2 trial to test the hypothesis that restricting intake of carbohydrates, leading to weight loss and improved insulin control in overweight patients, would reduce the risk of the ADT-associated side effects. ... Read More »

Radiotherapy versus Observation in Very Elderly Prostate Cancer Patients

San Diego—The aging population and the improvement of life expectancy have contributed to an increase in the proportion of patients ≥80 years of age with prostate cancer. However, according to Paolo Dell’Oglio, MD, and colleagues, there are few data on the management of these patients. The researchers recently conducted a study to compare survival in elderly men with localized prostate ... Read More »